OBJECTIVE To examine early leucocyte responses and neutrophil activation in acute myocardial infarction treated by streptokinase and to relate the findings to coronary recanalisation and indices of myocardial damage in order to provide further information about the role of neutrophils in the evolution of injury. DESIGN Group analysis of paired blood samples, obtained before streptokinase trea...

BACKGROUND Worldwide, streptokinase remains the most used thrombolytic agent for the treatment of myocardial infarction. Recombinant streptokinase, from E. coli, is increasingly used in developing countries as a biosimilar of native streptokinase; however, potency assignments relative to the WHO International Standard (IS) are highly variable with potentially dangerous consequences. A proportio...

Accepted for publication 13 January 1992 Abstract Objective-To examine the induction of antistreptokinase antibodies after giving streptokinase or anistreplase to patients with acute myocardial infarction. Design-Patients were randomly allocated to receive either 15 x 10' IU, streptokinase or 30U anistreplase in a double blind study. Blood samples were collected immediately before treatment and...

The steady state kinetic parameters of activation of human Gluand Lys-plasminogens and bovine plasminogen by streptokinase and its equimolar complexes with Gluand Lys-plasminogen, Lys-plasmin, and the plasmin-derived light(B) chain, as well as urokinase, were determined. Activation rates were measured at pH 6.0 and 30” by determining the initial velocity of Na-Cbz-L-lysine-p-nitrophenyl ester h...

BACKGROUND The most important complication following cardiac catheterization required urgent therapeutic management is vessel obstruction and arterial thrombosis. The morbidity following this complication can be decreased by surgery intervention and/or thrombolytic drugs. OBJECTIVES In this study we evaluated the effects of ranitidine and hydrocortisone on pediatric patients with congenital h...

Pulmonary edema is rare in patients with pulmonary embolism and to our knowledge has not been described in association with thrombolytic therapy. We describe a patient with massive pulmonary embolism in whom the adult respiratory distress syndrome (ARDS) developed shortly after a course of streptokinase therapy. The possible association between streptokinase therapy or pulmonary embolism and AR...

Background. Streptokinase is a routinely used thrombolytic agent that is immunogenic and relatively inefficient toward platelet-rich thrombus, whereas staphylokinase is a poorly studied fibrinolytic agent. Here, the comparative immunogenicity and thrombolytic properties toward arterial platelet-rich thrombus and venous whole blood clots of streptokinase and recombinant staphylokinase were studi...

Single-plane contrast ventriculography was performed on admission and before hospital discharge in more than 200 patients with acute myocardial infarction participating in a series of prospective clinical trials including intracoronary streptokinase, percutaneous transluminal coronary angioplasty (PTCA), intravenous tissue plasminogen activator (rt-PA) and thrombolysis (intravenous rt-PA or str...

BACKGROUND Streptokinase is the most widely used thrombolytic agent and can now be made using recombinant DNA technology. The present trial was initiated to assess an indigenous recombinant streptokinase (Shankinase, r-SK). AIM To compare the efficacy and safety of indigenous recombinant streptokinase (Shankinase, r-SK) and natural streptokinase (Streptase, n-SK). SETTINGS AND DESIGN Double...

Dear Sir In the recently published Task force report, under section ‘Fibrinolytic regimens’, the authors recommend not to readminister streptokinase for at least 10 years. The reference supporting this statement is Ref. 51. After evaluating this paper and looking into the literature my comments are as follows: The referenced publication only contains data up to 7.5 years. In so far any comment ...